Leading the science of longevity.
Circulate Health is the industry pioneer in therapeutic plasma exchange for longevity. We conducted the first single-blind human clinical trial to demonstrate a measurable reduction in biological age. We hold the patents shaping how TPE is delivered. And our peer-reviewed research on microplastics burden removal is redefining what’s possible in preventive medicine.
Our approach
Apply what’s proven, measure what changes, and keep advancing the science.
The Circulate Trial
A Breakthrough in Longevity Science
The Circulate Trial was the first single-blind human clinical trial to evaluate how therapeutic plasma exchange may influence biological age and immune markers associated with longevity. Conducted in collaboration with the Buck Institute for Research on Aging, this landmark study showed an average 2.6-year reduction in biological age after six TPE sessions.
Study highlights:
Albumin + antibody group:
Estimated biological age decreased by ~2.6 years
Albumin-only group:
Estimated biological age decreased by ~1 year
Control group (saline):
Biological age estimates increased over the study period
What was tracked:
Repeated biological age testing and blood-based measures over time
Research in partnership
We’re advancing longevity science—partnering with our clinics to expand research, explore new indications, and strengthen evidence that guides how TPE protocols are developed, adapted within the clinic setting and delivered. Together, we continue refining how care is delivered so it stays consistent, appropriate, and grounded in evidence.
Interested in offering TPE at your clinic?
Circulate supports clinics with standardized protocols, specialized staffing, and a consistent care model for delivering Therapeutic Plasma Exchange.